Commentary|Videos|November 21, 2026

FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group of POLARIS-AD Trial, Benjamin Greenberg's, MD, MHS, Insights From the 2026 RNDS

Neurology News Network for the week ending November 21st, 2026. [WATCH TIME: 6 minutes]

WATCH TIME: 6 minutes | Captions are auto-generated and may contain errors.

Below is a transcript of the video.

Welcome to the Neurology News Network, my name is Louie Pasculli and here’s a look at some of the top stories in Neurology.

The FDA has been extremely busy this week, approving two new therapies for adults with acetylcholine receptor antibody-positive generalized myasthenia gravis, further expanding treatment options for this patient population. First, the agency approved gefurulimab, (Klygefa; Alexion) a once-weekly, self-administered subcutaneous therapy that is a complement C5 inhibitor. Its approval was supported by the phase 3 PREVAIL trial, in which patients receiving gefurulimab demonstrated a 4.2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores at week 26, compared with a 2.6-point improvement with placebo.1

The FDA also approved cemdisiran, (Livsayis; Regeneron Pharmaceuticals)which is a the first small interfering RNA, or siRNA, therapy approved for gMG and is administered subcutaneously once every 3 months. The approval was supported by the phase 3 NIMBLE trial, in which patients receiving cemdisiran experienced a 4.5-point improvement in MG-ADL scores at week 24, compared with a 2.2-point improvement with placebo. Improvements were also observed on the Quantitative Myasthenia Gravis scale, with treatment effects emerging as early as 2 weeks after initiation.2

Although both therapies target complement component C5, they use different mechanisms to achieve this effect. Gefurulimab directly binds C5, while cemdisiran uses RNA interference to reduce the liver’s production of C5. Their dosing schedules also offer different options for patients, with weekly administration for gefurulimab compared with quarterly dosing for cemdisiran. Both therapies carry boxed warnings for serious meningococcal infections and require meningococcal vaccination before treatment. Together, these approvals introduce additional complement-targeting options for adults with AChR antibody-positive gMG, including therapies with less frequent subcutaneous dosing schedules.1,2

Switching gears,the global, randomized, double-blind, placebo-controlled phase 3 POLARIS-AD (NCT05531526) trial showed that AR1001 (AriBio) displayed clinical decline by 31% on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) in the prespecified monotherapy population of individuals with early Alzheimer disease (AD), according to topline results announced by the company.1 The investigational, once-daily oral phosphodiesterase 5 (PDE5) inhibitor did not achieve statistical significance on the same end point in the overall trial population.

The data were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held November 16 to 19, 2026, in Boston, Massachusetts. Sharon J. Sha, MD, MS, chief of the Memory Disorders Division at Stanford University and global principal investigator of POLARIS-AD, presented the 52-week findings. The monotherapy population, one of 2 prespecified primary analysis populations, consisted of participants who were not receiving an acetylcholinesterase inhibitor or memantine at baseline.1

"The CDR-SB finding in the prespecified Monotherapy population and the safety profile are encouraging," Sha said in a statement.1 "The secondary endpoints and biomarker findings warrant further evaluation alongside the Overall population outcome to understand AR1001's therapeutic effects in early Alzheimer's disease."

In other news, The Siegel Rare Neuroimmune Association (SRNA) held its 2026 Rare Neuroimmune Disorders Symposium (RNDS) October 15-17, bringing together patients, families, and clinicians for 3 days of sessions on the diagnosis and acute treatment, long-term symptom management, and research of rare neuroimmune disorders.4 The program included updates on diagnostic criteria for transverse myelitis (TM) and neuromyelitis optica spectrum disorder (NMOSD), as well as research presentations on the phase 3 METEOROID trial (NCT05271409) of satralizumab (Enspryng; Genentech) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

In METEOROID study, findings showed that satralizumab reduced the risk of relapse by 68% vs placebo (P = .0025), with 87% of treated patients relapse-free at 48 weeks compared with 67% of those on placebo.5,6 In September 2026, the FDA granted priority review to the supplemental biologics license application for satralizumab in MOGAD, with a decision expected by January 10, 2027.6

Benjamin Greenberg, MD, MHS, professor of neurology at UT Southwestern Medical Center, has taken part in the symposium for nearly 2 decades. At this year’s meeting, he co-led a diagnostic workup masterclass, moderated a panel of community members sharing their diagnostic journeys, and presented updates on the Q-Cell Study (NCT03887273), a phase 1 trial evaluating the transplantation of human glial restricted progenitor cells into the spinal cords of patients with TM.4,7

Greenberg has also long advocated for retiring the term “transverse myelitis” in favor of a more etiology-informed nomenclature for inflammatory myelopathies.8 Following the symposium, Greenberg spoke with NeurologyLive® to share the key themes from this year’s RNDS and clinical trials clinicians should watch out for in the future. In the conversation, he also talked about how proposed updates to myelitis diagnostic criteria and nomenclature may reshape care, and the unmet needs, including mental health support, that patients raised at the meeting.

To read the full piece and to get more direct access to expert insight, head to NeurologyLive.com. Be sure to tune in next week to remain informed on the latest in neurology. I’m Louie Pasculli, thanks for watching Neurology News Network.

REFERENCES
1. KLYGEFA™ (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients. News release. Alexion, AstraZeneca Rare Disease. Published November 16, 2026. Accessed November 17, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/KLYGEFA-gefurulimab-gaks-approved-in-the-US-for-the-treatment-of-generalized-myasthenia-gravis-gMG-in-adult-patients.html
2. Livsayis™ (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis and only treatment with four-times-a-year subcutaneous dosing. News release. Regeneron Pharmaceuticals, Inc. Published November 18, 2026. Accessed November 18, 2026. https://investor.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
3. AriBio Co., Ltd. AriBio's oral AR1001 meets primary efficacy objective in prespecified monotherapy population in phase 3 POLARIS-AD trial. News release. GlobeNewswire. November 16, 2026. Accessed November 17, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404242/0/en/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial.html
4. 2026 Rare Neuroimmune Disorders Symposium resource center. Siegel Rare Neuroimmune Association. Accessed November 13, 2026. https://wearesrna.org/resources/2026-rnds
5. Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial. Presented at: 2026 AAN Annual Meeting; April 18-22; Chicago, Illinois.
6. U.S. FDA grants priority review for Roche's enspryng for MOGAD, an autoimmune disease with no approved treatments. News release. Roche. September 9, 2026. Accessed November 13, 2026. https://www.roche.com/media/releases/med-cor-2026-09-10
7. Q study updates: expanded inclusion criteria and what’s next. Siegel Rare Neuroimmune Association. May 18, 2026. Accessed November 13, 2026. https://wearesrna.org/?p=79285
8. Blackburn KM, Greenberg BM. Revisiting Transverse Myelitis: Moving Toward a New Nomenclature. Front Neurol. 2020;11:519468. Published 2020 Sep 23. doi:10.3389/fneur.2020.519468

Related to this article